Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perampanel in mild-moderate PD
NCT00566462Phase 2Terminated
- Sponsor
- Eisai Co., Ltd.
- Start
- Oct 2007
- Primary completion
- Dec 2008
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing Perampanel with Placebo (2 arms). Primary endpoint: Change in Striatal [^123I]-Iodobenzamine (IBZM) Binding Following a Single Dose Carbidopa/Levodopa Challenge at 4 weeks. Started Oct 2007; status: terminated.
02
Drugs
perampanel
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00566462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00566462.